DE68917474T2 - Matrize mit immunomodulierender wirkung. - Google Patents

Matrize mit immunomodulierender wirkung.

Info

Publication number
DE68917474T2
DE68917474T2 DE68917474T DE68917474T DE68917474T2 DE 68917474 T2 DE68917474 T2 DE 68917474T2 DE 68917474 T DE68917474 T DE 68917474T DE 68917474 T DE68917474 T DE 68917474T DE 68917474 T2 DE68917474 T2 DE 68917474T2
Authority
DE
Germany
Prior art keywords
pct
matrix
adjuvants
date
saponins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68917474T
Other languages
English (en)
Other versions
DE68917474D1 (de
Inventor
Bror Morein
Karin Lovgren
Kristian Dalsgaard
Jan Thurin
Bo Sundquist
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE8901027A external-priority patent/SE8901027D0/xx
Priority claimed from SE8902780A external-priority patent/SE8902780D0/xx
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE68917474D1 publication Critical patent/DE68917474D1/de
Publication of DE68917474T2 publication Critical patent/DE68917474T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/256—Polyterpene radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE68917474T 1988-09-30 1989-09-28 Matrize mit immunomodulierender wirkung. Expired - Lifetime DE68917474T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25157688A 1988-09-30 1988-09-30
SE8901027A SE8901027D0 (sv) 1989-03-22 1989-03-22 Triterpenoider
SE8902780A SE8902780D0 (sv) 1989-08-16 1989-08-16 Corncerning qa-matrix
PCT/SE1989/000528 WO1990003184A1 (en) 1988-09-30 1989-09-28 Matrix with immunomodulating activity

Publications (2)

Publication Number Publication Date
DE68917474D1 DE68917474D1 (de) 1994-09-15
DE68917474T2 true DE68917474T2 (de) 1995-03-16

Family

ID=27355484

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68917474T Expired - Lifetime DE68917474T2 (de) 1988-09-30 1989-09-28 Matrize mit immunomodulierender wirkung.

Country Status (15)

Country Link
US (1) US5679354A (de)
EP (1) EP0436620B1 (de)
JP (1) JP2501650B2 (de)
AT (1) ATE109662T1 (de)
AU (1) AU632067B2 (de)
CA (1) CA1338888C (de)
DE (1) DE68917474T2 (de)
DK (1) DK175470B1 (de)
ES (1) ES2029758A6 (de)
FI (1) FI911537A0 (de)
HU (1) HUT56722A (de)
IE (1) IE65428B1 (de)
NZ (1) NZ230747A (de)
PT (1) PT91856B (de)
WO (1) WO1990003184A1 (de)

Families Citing this family (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291228B1 (en) 1988-08-03 2001-09-18 Vericore Limited Vaccine
GB8919819D0 (en) * 1989-09-01 1989-10-18 Coopers Animal Health Complexes having adjuvant activity
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
SE502569C2 (sv) * 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
WO1994022476A1 (en) * 1993-03-29 1994-10-13 Pfizer Inc. Multicomponent clostridial vaccines using saponin adjuvants
NL9301690A (nl) * 1993-08-12 1995-04-18 Seed Capital Investments Verbindingen met adjuvans-activiteit.
WO1995009179A1 (en) * 1993-09-30 1995-04-06 Seed Capital Investments (Sci) B.V. Compounds with adjuvant activity
AUPM500494A0 (en) * 1994-04-12 1994-05-05 Minister For Agriculture & Rural Affairs For The State Of New South Wales, The Composition for use in increasing mucosal immunity
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
AU686891B2 (en) * 1994-10-12 1998-02-12 Iscotec A.B. Saponin preparations and use thereof in iscoms
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US20010053365A1 (en) * 1995-04-25 2001-12-20 Smithkline Beecham Biologicals S.A. Vaccines
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
CN1165628A (zh) * 1996-02-14 1997-11-26 浙江农业大学 茶油饼中提取三萜类皂素作为添加剂的应用
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
US5977081A (en) * 1997-05-20 1999-11-02 Galenica Pharmaceuticals, Inc. Triterpene saponin analogs having adjuvant and immunostimulatory activity
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
FR2781055B1 (fr) * 1998-07-09 2000-10-13 Immunotech Sa Reactif et methode pour la permeabilisation et l'identification des erythrocytes
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
AU5565599A (en) 1998-08-14 2000-03-06 Dante J. Marciani Chemically modified saponins and the use thereof as adjuvants
JP5084984B2 (ja) 1999-02-17 2012-11-28 シーエスエル、リミテッド 免疫原複合体およびそれに関する方法
US6649170B1 (en) * 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
US6432411B1 (en) * 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
CA2383105C (en) * 1999-09-24 2010-01-26 Smithkline Beecham Biologicals S.A. Intranasal influenza virus vaccine
WO2001037869A1 (en) * 1999-11-19 2001-05-31 Csl Limited Vaccine compositions
US8163289B2 (en) * 2001-03-09 2012-04-24 Iterative Therapeutics, Inc. Methods and compositions involving polymeric immunoglobulin fusion proteins
WO2002072608A2 (en) * 2001-03-09 2002-09-19 University Of Chicago POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
DK1377320T3 (da) 2001-04-04 2009-02-09 Nordic Vaccine Technology As Polynukleotidbindingskomplekser omfattende steroler og saponiner
US6861410B1 (en) 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
US20050287170A1 (en) * 2002-12-11 2005-12-29 Hawaii Biotech, Inc. Subunit vaccine against West Nile viral infection
AU2003300831A1 (en) * 2002-12-11 2004-06-30 Hawaii Biotech, Inc. Recombinant vaccine against flavivirus infection
US7521187B2 (en) * 2002-12-23 2009-04-21 Vical Incorporated Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
CA2508281C (en) * 2002-12-23 2011-08-09 Vical Incorporated Method for producing sterile polynucleotide based medicaments
JP2006515024A (ja) * 2003-01-29 2006-05-18 ファイザー・プロダクツ・インク Ｂｏｒｄｅｔｅｌｌａｂｒｏｎｃｈｉｓｅｐｔｉｃａに対するイヌワクチン
SE0300795D0 (sv) 2003-03-24 2003-03-24 Isconova Ab Composition comprising iscom particles and live micro-organisms
SE0301998D0 (sv) * 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005033278A2 (en) * 2003-09-30 2005-04-14 Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus iscom
KR20090051129A (ko) * 2004-04-05 2009-05-20 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2006060723A2 (en) * 2004-12-03 2006-06-08 Vical Incorporated Methods for producing block copolymer/amphiphilic particles
EP1838341B1 (de) 2005-01-20 2013-08-14 Isconova AB Impfstoffzusammensetzung mit einem fibronectinbindenden protein oder einem fibronectinbindenden peptid
EP1764369A1 (de) 2005-09-16 2007-03-21 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
ES2325243B1 (es) 2008-02-27 2011-05-04 Universidad De Granada Antigeno recombinante.
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
ES2569907T3 (es) * 2008-06-27 2016-05-13 Zoetis Services Llc Composiciones adyuvantes novedosas
NZ592977A (en) 2008-12-09 2013-01-25 Pfizer Vaccines Llc IgE CH3 PEPTIDE VACCINE
KR101450958B1 (ko) 2009-04-30 2014-10-15 콜레이 파마시티컬 그룹, 인코포레이티드 폐렴구균 백신 및 그의 용도
NZ618391A (en) 2009-07-30 2015-07-31 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
KR101660578B1 (ko) 2009-09-03 2016-09-27 화이자 백신스 엘엘씨 Ｐｃｓｋ９ 백신
CA2777159A1 (en) 2009-10-22 2011-04-28 Universitat Leipzig Detection of a circovirus in calves suffering from bovine neonatal pancytopenia
WO2011077309A2 (en) 2009-12-22 2011-06-30 Pfizer Vaccines Llc Vaccine compositions
WO2011154863A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
EP2575868A1 (de) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige-ch3-peptidimpfstoff
JP6133207B2 (ja) 2010-07-23 2017-05-24 イスコノバ アーベー インフルエンザワクチン
AP3390A (en) 2010-09-20 2015-08-31 Crucell Holland Bv Therapeutic vaccination against active tuberculosis
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
WO2012158643A1 (en) 2011-05-13 2012-11-22 Ah Usa 42 Llc Hendra and nipah virus g glycoprotein immunogenic compositions
CA2845884A1 (en) 2011-08-22 2013-02-28 Cangene Corporation Clostridium difficile antibodies
DK3311827T3 (da) * 2011-10-03 2023-04-03 Canqura Oncology Ab Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærere for amfipatiske eller hydrofobe molekyler inden for det medicinske område, inklusiv cancerbehandling, samt fødevarerelaterede forbindelser
CA2857087C (en) 2011-11-28 2021-05-25 Crucell Holland B.V. Influenza virus vaccines and uses thereof
SI2825640T1 (sl) 2012-03-12 2016-08-31 Crucell Holland B.V. Šarže rekombinantnega adenovirusa s spremenjenimi konci
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
WO2013138334A1 (en) * 2012-03-12 2013-09-19 Advanced Bioadjuvants, Llc Adjuvant and vaccine compositions
CN104334188B (zh) 2012-03-22 2016-08-24 克鲁塞尔荷兰公司 抗rsv疫苗
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
EP2659906A1 (de) 2012-05-01 2013-11-06 Affiris AG Zusammensetzungen
EP2659908A1 (de) 2012-05-01 2013-11-06 Affiris AG Zusammensetzungen
EP2659907A1 (de) 2012-05-01 2013-11-06 Affiris AG Zusammensetzungen
ES2597832T3 (es) 2013-03-08 2017-01-23 Janssen Vaccines & Prevention B.V. Vacuna acelular contra la tosferina
WO2014163558A1 (en) 2013-04-01 2014-10-09 Moreinx Ab Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
PL2988780T3 (pl) 2013-04-25 2019-06-28 Janssen Vaccines & Prevention B.V. Stabilizowane rozpuszczalne prefuzyjne polipeptydy F RSV
WO2014191435A1 (en) 2013-05-30 2014-12-04 Crucell Holland B.V. Influenza virus vaccines and uses thereof
AP2015008893A0 (en) 2013-06-17 2015-12-31 Crucell Holland Bv Stabilized soluble pre-fusion rsv f polypeptides
US20160151479A1 (en) 2013-07-02 2016-06-02 Crucell Holland B.V. Method for preparing virosomes
WO2015000831A1 (en) 2013-07-02 2015-01-08 Crucell Holland B.V. Method for preparing virosomes
US10093978B2 (en) 2013-08-12 2018-10-09 Genentech, Inc. Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
CA2924526A1 (en) 2013-09-19 2015-03-26 Paul Joseph Dominowski Water-in-oil emulsions comprising immunostimulatory oligonucleotides
WO2015095012A1 (en) 2013-12-16 2015-06-25 Zoetis Llc Hendra and nipah virus g glycoprotein immunogenic compositions
AU2015208821B2 (en) 2014-01-21 2017-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
EP3145546B1 (de) 2014-02-19 2020-12-09 Emergent BioSolutions Canada Inc. Monoklonale marburg-antikörper
CN112390887B (zh) 2014-04-10 2023-09-26 台湾浩鼎生技股份有限公司 抗体、产生所述抗体的杂交瘤、及其用途
CR20160561A (es) 2014-05-01 2017-05-03 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos
AU2015286721B2 (en) 2014-07-10 2019-11-21 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
CN107001449A (zh) 2014-10-15 2017-08-01 芝诺锡拉公司 具有降低的免疫原性的组合物
LT3215187T (lt) 2014-11-04 2018-12-27 Janssen Vaccines & Prevention B.V. Terapinės hpv16 vakcinos
FI3244917T3 (fi) 2015-01-15 2023-05-25 Pfizer Immunogeenisiä koostumuksia pneumokokkirokotteissa käytettäväksi
PL3244920T3 (pl) 2015-01-16 2023-09-25 Zoetis Services Llc Szczepionka przeciw pryszczycy
AU2016249798B2 (en) 2015-04-14 2022-05-26 Janssen Vaccines And Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
US10576131B2 (en) 2015-06-03 2020-03-03 Affiris Ag IL-23-p19 vaccines
WO2017005851A1 (en) 2015-07-07 2017-01-12 Affiris Ag Vaccines for the treatment and prevention of ige mediated diseases
EA039065B1 (ru) 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
JP6840718B2 (ja) 2015-07-07 2021-03-10 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定化された可溶性融合前ｒｓｖ ｆポリペプチド
TWI756893B (zh) 2015-07-21 2022-03-01 美商輝瑞股份有限公司 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
SG10202001501QA (en) 2015-08-20 2020-04-29 Janssen Vaccines & Prevention Bv Therapeutic hpv18 vaccines
CA2997181A1 (en) 2015-09-02 2017-03-09 Janssen Vaccines & Prevention B.V. Stabilized viral class i fusion proteins
EP3344291A4 (de) 2015-09-03 2019-04-10 Novavax, Inc. Impfstoffzusammensetzungen mit verbesserter stabilität und immunogenität
PL3307322T3 (pl) 2015-09-04 2021-07-05 Primatope Therapeutics Inc. Humanizowane przeciwciała anty-cd40 i ich zastosowania
CN108350605A (zh) 2015-09-04 2018-07-31 台湾浩鼎生技股份有限公司 聚糖阵列以及使用方法
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
BR112018010805A2 (pt) 2015-12-23 2018-11-27 Pfizer Inc. mutantes de proteína f de rsv
BR112018070097A2 (pt) 2016-03-29 2019-02-12 Obi Pharma, Inc. anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
PE20190433A1 (es) 2016-04-05 2019-03-21 Janssen Vaccines And Prevention B V Vacuna contra vrs
ES2858315T3 (es) 2016-04-05 2021-09-30 Janssen Vaccines & Prevention Bv Proteína F de prefusión de VRS soluble estabilizada para uso en la profilaxis de la infección por VRS
SG11201809024UA (en) 2016-04-22 2018-11-29 Obi Pharma Inc Cancer immunotherapy by immune activation or immune modulation via globo series antigens
JP7053491B2 (ja) 2016-05-02 2022-04-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー 治療用ｈｐｖワクチン組み合わせ
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
MX2018015540A (es) 2016-06-20 2019-04-11 Janssen Vaccines & Prevention Bv Promotor bidireccional potente y equilibrado.
JP7229151B2 (ja) 2016-07-14 2023-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｐｖワクチン
CN110072545A (zh) 2016-07-27 2019-07-30 台湾浩鼎生技股份有限公司 免疫原性/治疗性聚糖组合物及其用途
KR102528998B1 (ko) 2016-07-29 2023-05-03 오비아이 파머 인코퍼레이티드 인간 항체, 제약 조성물 및 방법
TWI822055B (zh) 2016-11-21 2023-11-11 台灣浩鼎生技股份有限公司 共軛生物分子、醫藥組成物及方法
DK3570879T3 (da) 2017-01-20 2022-04-11 Pfizer Immunogene sammensætninger til anvendelse i pneumokokvacciner
CN110268061A (zh) 2017-02-09 2019-09-20 扬森疫苗与预防公司 用于表达异源基因的有效的短启动子
JP2020519663A (ja) 2017-05-17 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物
WO2019023196A1 (en) 2017-07-24 2019-01-31 Novavax, Inc. METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASE
AU2018333566A1 (en) 2017-09-15 2020-02-27 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
SG11202006399VA (en) 2018-01-23 2020-08-28 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
WO2019173438A1 (en) 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
KR20210004959A (ko) 2018-03-19 2021-01-13 노바백스, 인코포레이티드 다가 인플루엔자 나노입자 백신
GB201807303D0 (en) 2018-05-03 2018-06-20 London School Of Hygeine & Tropical Medicine Glyconjugate vaccines
MX2020012418A (es) 2018-05-23 2021-04-28 Adc Therapeutics Sa Adyuvante molecular.
TW202035444A (zh) 2018-06-27 2020-10-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JOP20210106A1 (ar) 2018-11-13 2023-01-30 Janssen Vaccines And Prevention B V بروتينات rsv f سابقة الاندماج مستقرة
JP2022512345A (ja) 2018-12-12 2022-02-03 ファイザー・インク 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用
JP2022528158A (ja) 2019-04-10 2022-06-08 ファイザー・インク コンジュゲート化莢膜糖抗原を含む免疫原性組成物、それを含むキットおよびその使用
EP3959228A1 (de) 2019-04-25 2022-03-02 Janssen Vaccines & Prevention B.V. Rekombinante influenza-antigene
US20220193219A1 (en) 2019-05-15 2022-06-23 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
US20220273787A1 (en) 2019-05-15 2022-09-01 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
CA3152957A1 (en) 2019-09-05 2021-03-11 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
IL292494A (en) 2019-11-01 2022-06-01 Pfizer Preparations of Escherichia coli and their methods
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
WO2021155323A1 (en) 2020-01-31 2021-08-05 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for preventing and treating coronavirus infection-sars-cov-2 vaccines
EP4107170A2 (de) 2020-02-23 2022-12-28 Pfizer Inc. <smallcaps/>? ? escherichia coli ? ? ? -zusammensetzungen und verfahren dafür
CN115884786A (zh) 2020-05-11 2023-03-31 杨森制药公司 SARS-CoV-2疫苗
JP2023525785A (ja) 2020-05-11 2023-06-19 ヤンセン ファーマシューティカルズ，インコーポレーテッド 安定化コロナウイルススパイクタンパク質をコードするｒｎａレプリコン
CA3183086A1 (en) 2020-05-11 2021-11-18 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
US20230233661A1 (en) 2020-06-29 2023-07-27 Janssen Vaccines & Prevention B.V. Vaccine combination against repiratory syncytial virus infection
WO2022008438A1 (en) 2020-07-06 2022-01-13 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
TW202227467A (zh) 2020-10-27 2022-07-16 美商輝瑞大藥廠 大腸桿菌組合物及其方法
KR20230097160A (ko) 2020-11-04 2023-06-30 화이자 인코포레이티드 폐렴구균 백신에 사용하기 위한 면역원성 조성물
CA3203043A1 (en) 2020-12-23 2022-06-30 Odile DUVAUX Composition of pig polyclonal antibody for its use to treat and/or prevent antibody-dependent macrophage pro-inflammatory cytokine release in a passive anti-infectious immunotherap
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022147373A1 (en) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
JP2024509756A (ja) 2021-02-19 2024-03-05 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定化された融合前ｒｓｖ ｆｂ抗原
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
WO2022207839A2 (en) 2021-04-01 2022-10-06 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023047349A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
WO2023047348A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023110618A1 (en) 2021-12-16 2023-06-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2023196634A2 (en) 2022-04-08 2023-10-12 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2023217988A1 (en) 2022-05-12 2023-11-16 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
GB202209588D0 (en) 2022-06-29 2022-08-10 Plant Bioscience Ltd Methods and compositions
WO2024017682A1 (en) 2022-07-18 2024-01-25 Janssen Vaccines & Prevention B.V. Rsv immunogens
WO2024030856A2 (en) 2022-08-01 2024-02-08 Flagship Pioneering Innovations Vii, Llc Immunomodulatory proteins and related methods
WO2024061757A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
WO2024061759A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized coronavirus s proteins
WO2024061753A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized trimeric class i fusion proteins
WO2024074584A1 (en) 2022-10-06 2024-04-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins
WO2024104947A2 (en) 2022-11-14 2024-05-23 Janssen Vaccines & Prevention B.V. Influenza b virus vaccines and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1503388A (en) * 1975-07-01 1978-03-08 Inverni Della Beffa Spa Pharmaceutically active complexes and pharmaceutical compositions containing them
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
ATE71303T1 (de) * 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
CA1331443C (en) * 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
DE3813570A1 (de) * 1988-04-22 1989-11-09 Fraunhofer Ges Forschung Verfahren zum fuegen von werkstuecken aus aufschmelzbarem werkstoff mit laserstrahlung

Also Published As

Publication number Publication date
WO1990003184A1 (en) 1990-04-05
FI911537A0 (fi) 1991-03-28
HU895758D0 (en) 1991-08-28
US5679354A (en) 1997-10-21
HUT56722A (en) 1991-10-28
EP0436620B1 (de) 1994-08-10
DK175470B1 (da) 2004-11-01
IE65428B1 (en) 1995-11-01
ATE109662T1 (de) 1994-08-15
DK55891A (da) 1991-05-29
EP0436620A1 (de) 1991-07-17
PT91856B (pt) 1995-07-03
AU632067B2 (en) 1992-12-17
JPH04501714A (ja) 1992-03-26
JP2501650B2 (ja) 1996-05-29
CA1338888C (en) 1997-02-04
NZ230747A (en) 1992-05-26
PT91856A (pt) 1990-03-30
ES2029758A6 (es) 1992-09-01
DE68917474D1 (de) 1994-09-15
IE893066L (en) 1990-03-30
AU4337489A (en) 1990-04-18
DK55891D0 (da) 1991-03-27

Similar Documents

Publication Publication Date Title
ATE109662T1 (de) Matrize mit immunomodulierender wirkung.
DE69939706D1 (de) Verbesserte adjuvant zusammensetzungen auf basis von saponin und damit zusammenhängende methoden
CA2302554A1 (en) Oil in water emulsions containing saponins
DK40484D0 (da) Polysaccharid/protein-konjugat,fremgangsmaade til fremstilling deraf og dets anvendelse i en vaccine
AU4324996A (en) Novel cyclodextrin-derivatives and methods for the preparation thereof
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
PT98156A (pt) Um processo de preparacao de uma composicao de vacina
JPS5231839A (en) Drug for cosmetics and permanent wave in combination
PT854924E (pt) Antigenios de leishmania para uso na terapia e diagnostico da leishmaniose
DE69206976D1 (de) Verfahren zur inaktivierung von umhüllten viren und sperma
ATE249841T1 (de) Immunogene zubereitungen
FI925649A0 (fi) Karboxivinylpolymerer med newtonsk viskositet
SE9402880D0 (sv) New peptide derivatives
BR9001974A (pt) Aparelho para pressurizar fluidos de poco de descida no poco,aparelho para assentar um obturador inflavel dentro de um poco subterraneo e processo para ativar um dispositivo de obturador inflavel dentro de um poco subterraneo
ES2117267T3 (es) Metodo para encapsular sustancias en biocapsulas.
DE69114796T2 (de) Antioxydantsystem auf Basis einer basischen Aminosäure und eines Tocopherols.
PT835309E (pt) Vacina contra agentes infecciosos composicao para o tratamento e a prevencao das infeccoes por hiv
NL180008B (nl) Werkwijze voor het bereiden van herbicide preparaten alsmede werkwijze voor het bereiden van voor toepassing in dergelijke preparaten geschikte 1,2-dimethyl-3,5-difenylpyrazoliumverbindingen.
NO911049L (no) Matrise med immun-modulerende aktivitet.
SE9600646D0 (sv) Vaccin
BR8902460A (pt) Processo para preparacao de hidrolisado de proteina de baixa imunogenicidade e antigenicidade,para uso enteral
NL7809733A (nl) Peptiden, werkwijze ter bereiding van deze peptiden en de toepassing ervan in therapeutische preparaten.
ITMI932171A1 (it) Procedimento per l&#39;estrazione di colori naturali mediante bentonite
MX9710523A (es) Vacunas contra hepatitis c.
IT8740039A0 (it) Metodo per l&#39;affilatura di coltelli per uso casalingo e da macellazione

Legal Events

Date Code Title Description
8364 No opposition during term of opposition